The earnings call presented a mix of strong financial growth and pipeline progress, particularly in Specialty Medicines, offset by challenges in the vaccine segment and specific market difficulties. The resolution of Zantac litigation is a positive development, yet the financial impact from it and the expected pressures from the U.S. Inflation Reduction Act present challenges.

Company Guidance

In the Q3 2024 earnings call for GSK, the company reported a 9% sales growth and 19% profit growth year-to-date, demonstrating strong performance in Specialty Medicines and resilience across its portfolio. Excluding COVID, sales for the quarter grew 2% and 9% year-to-date, with standout growth in Specialty Medicines at 19% and double-digit increases in HIV, Respiratory/Immunology, and Oncology. Despite challenges, such as lower sales in Vaccines due to decreased Arexvy and Shingrix sales, the company maintained strong market shares for these vaccines. GSK highlighted significant advancements in its pipeline, including filing Blenrep in multiple regions and planning for major product launches in 2025. The company's core operating profit and core EPS growth increased by 5%, supported by effective cost management, leading to GBP 5.3 billion cash generated from operations year-to-date. GSK plans to continue driving competitive growth with anticipated sales growth of 7% to 9% and double-digit profit growth for 2024, reinforcing its confidence in its long-term outlooks for 2026 and 2031.

Strong Financial Performance

GSK reported a 9% sales growth and 19% profit growth year-to-date. Specialty Medicines showed strong performance with a 19% increase, and HIV, Respiratory/Immunology, and Oncology witnessed double-digit growth.

Progress in Pipeline Development

GSK made considerable progress in its pipeline with 11 positive Phase III readouts and plans for five major new product approvals next year, including Blenrep, depemokimab, and a new meningitis vaccine.

Specialty Medicines and General Medicines Growth

Specialty Medicines grew by 19% and General Medicines by 7%, with significant contributions from Oncology and the HIV portfolio.

Resolution of Zantac Litigation

GSK resolved the majority of Zantac litigation, removing a major perceived risk for the company.

Enhanced Cash Flow

Cash generated from operations reached GBP 5.3 billion year-to-date, supporting pipeline investment and shareholder returns.

---

GlaxoSmithKline (GSK) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GSK Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 05, 2025	2024 (Q4)	0.50 / -	0.736	―	―	―
Oct 30, 2024	2024 (Q3)	1.15 / 1.29	1.222	5.81% (+0.07)
Jul 31, 2024	2024 (Q2)	0.98 / 1.11	1.003	11.17% (+0.11)
May 01, 2024	2024 (Q1)	0.92 / 1.08	0.923	16.68% (+0.15)
Jan 31, 2024	2023 (Q4)	0.74 / 0.74	0.636	15.72% (+0.10)
Nov 01, 2023	2023 (Q3)	1.11 / 1.22	1.075	13.67% (+0.15)
Jul 26, 2023	2023 (Q2)	0.89 / 1.00	0.835	20.12% (+0.17)
Apr 26, 2023	2023 (Q1)	0.83 / 0.92	0.829	11.34% (+0.09)
Feb 01, 2023	2022 (Q4)	0.55 / 0.64	0.701	-9.27% (-0.06)
Nov 02, 2022	2022 (Q3)	0.90 / 1.07	1.014	6.02% (+0.06)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

GSK Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Oct 30, 2024	$37.75	$36.60	-3.05%
Jul 31, 2024	$38.97	$37.99	-2.51%
May 01, 2024	$40.28	$41.38	+2.73%
Jan 31, 2024	$37.63	$37.97	+0.90%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---